Comparative Pharmacology
Head-to-head clinical analysis: MOBAN versus PERSERIS KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOBAN versus PERSERIS KIT.
MOBAN vs PERSERIS KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MOBAN (molindone) is an antipsychotic agent with mechanism of action not fully defined, but believed to involve dopamine D2 receptor blockade in the mesolimbic system, with minimal extrapyramidal effects due to weak D2 binding and possible serotonergic modulation.
Risperidone, the active component of PERSERIS, is an atypical antipsychotic with antagonist activity at dopamine D2 and serotonin 5-HT2A receptors. It also binds to α1-adrenergic, α2-adrenergic, and histamine H1 receptors.
Oral: 50-100 mg/day in 3-4 divided doses, increase to 225 mg/day for severe conditions; maximum 400 mg/day. IM: 50-100 mg every 4-6 hours; maximum 400 mg/day.
Subcutaneous injection: 90 mg every 28 days for maintenance treatment of schizophrenia.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours for parent drug; active metabolite (molindone) half-life ~12-15 hours; steady-state reached in 2-3 days.
Terminal elimination half-life is approximately 15 days (range 10-20 days) for the extended-release injectable formulation, reflecting slow release from the depot and sustained plasma concentrations.
Renal: 70-80% as metabolites and unchanged drug; biliary/fecal: ~20%.
Primarily hepatic metabolism via CYP2D6 and CYP3A4; approximately 30-40% of a dose is excreted in urine as metabolites, with less than 1% as unchanged drug. Biliary/fecal elimination accounts for about 60-70%.
Category C
Category C
Antipsychotic
Antipsychotic